ArticleResearch square2025
Intramuscular delivery of recombinant AAV expressing EpoR76E improves memory and is neuroprotective in 5xFAD transgenics.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Converging evidence suggests that erythropoietin (Epo) may be effective in alleviating symptoms of many neurological conditions, including traumatic brain injury and neurodegenerative disorders. However, a limitation to its use as a therapeutic agent is the risk associated with stimulation of hematopoietic pathways. To overcome this issue, we used a recombinant adeno-associated viral vector (AAV) designed to express a modified form of erythropoietin devoid of hematopoietic activity, EpoR76E. Our previous research showed that AAV.EpoR76E prevented motor impairments and mitigated loss of dopaminergic neurons in the MPTP mouse model of Parkinson's disease. In the present study, a single intramuscular injection of AAV expressing EpoR76E prevented cognitive decline in the 5xFAD transgenic model of Alzheimer's disease. Consistent with this, AAV-EpoR76E prevented the age-related loss of pre-and post-synaptic proteins synaptophysin and PSD-95 normally seen in 5xFAD transgenics. Additionally, the treatment reduced soluble and aggregated amyloid-β levels in 5xFAD mice, and prevented the loss of neurons in the medial septum and vertical limb of the diagonal band, the primary cholinergic projections to the hippocampus. Together, these results suggest that AAV-EpoR76E might represent a novel therapeutic approach for Alzheimer's disease and other neurodegenerative disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.